BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

Crescendo will receive $40 million upfront, including a cash payment and an equity investment from BioNTech

11-Jan-2022 - BioNTech SE and Crescendo Biologics Ltd, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other ...

Crescendo Biologics Ltd. Raises $70 Million in Series B Financing

02-May-2018 - Crescendo Biologics Ltd announced that it has completed a $70 million (€57 million) Series B financing. The funds will be used to advance the development of its lead programme, CB307, which stimulates local activation of tumour-specific T-cells, into the clinic and further expand its internal ...

Crescendo Biologics first major milestone in collaboration with Takeda reached

18-Apr-2018 - Crescendo Biologics Ltd, the developer of multifunctional biologics, including targeted T-cell engagers, announced that it has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company Limited. The global, strategic, multi-target ...

Crescendo Biologics appoints new Chief Business Officer

16-Jun-2017 - Crescendo Biologics Ltd (Crescendo) announced that Edward J. “Tad” Stewart has joined the company as Chief Business Officer. Dr. Peter Pack, CEO of Crescendo Biologics commented: “Crescendo’s platform is delivering a robust pipeline of intrinsically differentiated, multi-functional therapeutics ...

Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award

29-May-2015 - Crescendo Biologics Limited announces it is expanding its antibody drug conjugate (ADC) programme with the support of a Biomedical Catalyst Award from the UK’s innovation agency, Innovate UK. This feasibility award will enable the validation and development of Humabody Drug Conjugates (HDCs) a ...

Crescendo announces the Crescendo Mouse

Technology generates superior human single domain antibody VH fragments in a transgenic mouse

22-Jan-2013 - Crescendo Biologics Limited announces the Crescendo Mouse, an antibody fragment technology which allows the generation of human single domain antibody VH fragments from a transgenic mouse. VH fragments are antibody-based therapeutic proteins that have applications beyond the scope of full length ...

Crescendo Biologics Appoints Matthew Roe as Chief Business Officer

24-Jun-2011 - Crescendo Biologics Limited announced the appointment of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from Genzyme Corporation where he was Senior Director, Business Development & Licensing.During a 23-year career at Genzyme, Matthew was active in licensing, alliance management, ...

Mike Romanos Appointed as CEO of Crescendo Biologics

10-Jan-2011 - Crescendo Biologics Limited announces the appointment of Mike Romanos as Chief Executive Officer. Dr Romanos has been Chief Scientific Officer of the company since May 2009 and has led the formation of the company and the development of its proprietary antibody fragment technologies. During this ...

Clive Dix Appointed as Chairman of Crescendo Biologics

12-Jan-2010 - Crescendo Biologics announced the appointment of Clive Dix as Chairman. Dr Dix will work closely with Mike Romanos, Chief Scientific Officer of Crescendo, to drive the development of the Company and its proprietary antibody fragment technologies following the recent £4.5 million seed round ...

Mike Romanos Appointed as CSO of Crescendo Biologics

15-Oct-2009 - Mike Romanos has been appointed Chief Scientific Officer of Crescendo Biologics and joins the Board as a Director. Dr Romanos will take leadership of the company and its proprietary antibody fragment technologies following a £4.5 million seed fundraising round led by Sofinnova Partners. Dr ...